# First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06657222/  
OnCo record `nct06657222` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TUB-030 in small-cell lung cancer, non-small-cell lung cancer and triple-negative breast cancer, run by Tubulis GmbH, now recruiting.

## Summary

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06657222 by Tubulis GmbH, with 250 participants planned, started 2024-12-13 and due to reach its primary completion in 2028-12. Interventions recorded: TUB-030.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06657222
- Phase: 1/2
- Setting: A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients With Advanced Solid Tumors (5-STAR 1-01)
- Sponsor: Tubulis GmbH
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT06657222: https://clinicaltrials.gov/study/NCT06657222

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- companies: [Tubulis (Gilead)](https://onco.cc/companies/tubulis/)

---
JSON: https://onco.cc/api/v1/entities/nct06657222.json